Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GC 101
- Development stage
- Phase 2
- Lead developer
- Shanghai Juncell Therapeutics
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
GC 101 is an autologous tumor-infiltrating lymphocyte (TIL) injection therapy developed by Shanghai Juncell Therapeutics. It is being investigated for the treatment of advanced breast cancer. The therapy involves expanding a patient's own TILs from resected tumor tissue or biopsies, followed by intravenous infusion into the patient after non-myeloablative (NMA) lymphodepletion treatment.
- Other names
- autologous natural TIL injectionautologous tumor-infiltrating lymphocytes GC101GC101 TILGC-101 TILGC 101 TIL
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on GC 101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GC 101.